← Back to Home

FDA Approves Gedatolisib Breast Cancer Therapy, Adding a Later-Line Option for the PIK3CA-Negative Population

This approval not only brings Celcuity’s first product to market, but also gives patients with hormone receptor-positive, HER2-negative metastatic breast cancer who lack a PIK3CA mutation a new option centered on the PI3K/mTOR pathway after endocrine therapy.

By SURL BioNews

For many patients with hormone receptor-positive, HER2-negative advanced breast cancer, continued disease progression after endocrine therapy and CDK4/6 inhibitors often means treatment options begin to narrow. On July 14, the U.S. FDA approved Celcuity’s gedatolisib, under the brand name Revtorpyk, for use in combination with fulvestrant, with the option of adding palbociclib, in adults with locally advanced or metastatic breast cancer in whom no PIK3CA mutation is detected, adding a new branch to this treatment sequence.

Gedatolisib is a PI3K/mTOR inhibitor that targets signaling pathways often involved in cancer cell growth and survival. This label specifically focuses on the population without PIK3CA mutations. Its clinical significance lies in the fact that the use of some PI3K-pathway drugs in the past has often been closely tied to PIK3CA mutation status; now, the FDA’s acceptance of a gedatolisib-centered combination therapy effectively extends the discussion of pathway inhibition to another group of patients.

The approval was based mainly on Study 1 of VIKTORIA-1. According to descriptions of the same event from the FDA and ASCO Post, this was an open-label, randomized, multicenter trial that enrolled 392 adult patients and assigned participants 1:1:1 to a three-drug combination of gedatolisib, fulvestrant, and palbociclib; a two-drug combination of gedatolisib and fulvestrant; or fulvestrant monotherapy. The trial’s comparator design allowed the study to directly assess whether the new combinations delayed disease worsening compared with fulvestrant alone.

The results showed that median progression-free survival was 9.3 months in the three-drug combination group, 7.4 months in the two-drug combination group, and 2.0 months in the fulvestrant monotherapy group. This difference supported the FDA’s efficacy interpretation; however, overall survival data were still immature at the time of the progression-free survival analysis. Therefore, what can currently be determined with greater certainty is the effect on delaying disease progression, and it cannot yet be interpreted as proven life extension.

ClinicalTrials.gov registration information also provides a broader trial background. VIKTORIA-1 is a phase 3, randomized, open-label, parallel-group study evaluating gedatolisib plus fulvestrant, with or without palbociclib, in HR-positive, HER2-negative locally advanced or metastatic breast cancer that progressed during or after prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor. The registration lists an overall estimated enrollment of 701 people and stratification by PIK3CA mutation status; this also reminds readers that the FDA approval corresponds to a specific subgroup and regulatory interpretation within the trial, not to all patients with advanced breast cancer.

Safety will be an unavoidable issue in clinical adoption. Label warnings summarized by ASCO Post include stomatitis, cutaneous adverse reactions, hyperglycemia, and embryo-fetal toxicity. These risks are not uncommon in therapies that inhibit related signaling pathways, but in real-world treatment of advanced breast cancer, patients have often already received multiple lines of therapy. How to balance efficacy, quality of life, and the risk of treatment discontinuation will determine how far this therapy can go.

For that reason, Revtorpyk’s approval is more like the addition of a viable route on the treatment map than a final destination. It provides a randomized-trial-supported option for patients without PIK3CA mutations whose disease has worsened after endocrine therapy; what will be more critical next is how physicians arrange two-drug or three-drug strategies based on prior treatment, comorbidities, metabolic risk, and patient preference, and whether follow-up data can fill in the answers on overall survival and long-term tolerability.

References

  1. FDA
  2. The ASCO Post
  3. ClinicalTrials.gov